People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This ...
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
10h
Hosted on MSNCelebrity weight loss drug to be offered in Colchester pharmacyA COLCHESTER pharmacy boss is “delighted” to offer a weight loss drug which has been used by celebrities through a new ...
A new study reveals a novel connection between aging of visceral adipose tissue and brain health. These findings are ...
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...
Higher adherence to the Mediterranean diet reduced the risk of obesity-related cancers, but not in the way researchers ...
Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...
Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The pharmaceutical company said it has launched 7.5 and 10 milligram single-dose vials ...
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results